Table of contents
- Trial overview
- Who was studied
- What was tested
- Study design and phase
- Outcomes measured
- What the results focus on
Trial overview
The source data includes one interventional study, which means researchers gave treatments and measured the results.[1] The study was completed and enrolled 740 people.[1] It studied patients with heart failure and included Imidapril Hydrochloride among several heart medicines used in the treatment setting.[1]
Who was studied
The study focused on symptomatic HF patients, meaning people with heart failure who had symptoms.[1] It included patients with LVEF < 50%, which means the heart’s main pumping chamber was sending out less blood than normal.[1] Patients were treated with standard of care, including ACEI or ARB therapy, or sacubitril/valsartan.[1]
What was tested
The brief summary says the study aimed to evaluate the efficacy and dose-response relationship of three target dose levels compared with placebo.[1] A dose-response relationship asks whether different doses lead to different effects.[1] The intervention list also shows many background heart medicines, including Imidapril Hydrochloride, as part of the treatment context described in the trial data.[1]
Study design and phase
This was a Phase 2 trial.[1] Phase 2 studies usually look at whether a treatment seems effective and help define the right dose range.[1] The study compared three target dose levels with placebo, which is a look-alike treatment used for comparison.[1]
Outcomes measured
The main outcome was change in log NT-proBNP from baseline to Week 16.[1] NT-proBNP is a blood marker that can rise when the heart is under stress.[1] Measuring the change over time helps researchers see whether the study treatment may improve heart failure-related strain.[1]
What the results focus on
Because the trial was completed, the main value of the record is in understanding the study question, the patient group, and the outcome that was measured.[1] The trial was designed to learn whether the tested treatment approach could lower NT-proBNP in symptomatic patients with reduced heart function.[1] The data also show that the study was done on top of usual heart failure treatment, which helps make the findings more relevant to everyday care settings.[1]
